XML 37 R20.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Income Taxes
 12 Months Ended
Apr. 30, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The components of the Company’s net loss before provision for income taxes for the fiscal years ended April 30, 2024, 2023 and 2022 were as follows (in thousands):
Fiscal Year Ended April 30,
202420232022
Domestic$(282,036)$(270,280)$(189,891)
Foreign3,132 2,116 (1,385)
Net loss before provision for income taxes$(278,904)$(268,164)$(191,276)
The components of the Company’s provision for income taxes for the fiscal years ended April 30, 2024, 2023 and 2022 were as follows (in thousands):
Fiscal Year Ended April 30,
202420232022
Current expense
Federal$— $— $— 
State293 306 310 
Foreign499 369 479 
Total792 675 789 
Deferred expense
Federal— — — 
State— — — 
Foreign— — — 
Total— — — 
Total provision for income taxes$792 $675 $789 
The reconciliation of U.S. federal statutory rate to the Company’s effective tax rate was follows (in thousands):
Fiscal Year Ended April 30,
202420232022
Expected benefit at federal statutory rate$(58,570)$(56,314)$(40,119)
State tax expense—net of federal benefit292 306 310 
Impact of foreign operations(158)(75)770 
Federal research and development credit(3,087)(2,489)(1,109)
Change in valuation allowance66,556 32,481 59,450 
Stock-based compensation(5,001)25,806 (19,152)
Meals and entertainment207 95 50 
Other permanent items553 865 589 
Total provision for income taxes$792 $675 $789 
The difference in the Company’s effective tax rate and the U.S. federal statutory tax rate is primarily due to recording a full valuation allowance on the Company’s U.S. deferred tax assets.
The components of deferred tax assets and liabilities as of April 30, 2024 and 2023 were as follows (in thousands):
As of April 30,
20242023
Deferred tax assets
Accrued payroll$5,542 $3,971 
Other accruals & reserves5,933 5,815 
Operating lease liability13,433 8,868 
Deferred revenue1,643 2,221 
Net operating losses141,157 116,111 
R&D tax credit15,001 10,302 
Stock based compensation13,263 10,595 
Capitalized R&D expenditure72,140 30,696 
Other626 457 
Gross deferred tax assets268,738 189,036 
Valuation allowance(252,682)(180,571)
Total deferred tax assets16,056 8,465 
Deferred tax liabilities
Prepaid expenses(1,986)(1,956)
Depreciation(9,808)(2,580)
Operating lease right-of-use assets(4,262)(3,929)
Total deferred tax liabilities(16,056)(8,465)
Net deferred tax assets (liabilities)$— $— 
In determining the need for a valuation allowance, the Company weighs both positive and negative evidence in the various jurisdictions in which it operates to determine whether it is more likely than not that its deferred tax assets are recoverable. In assessing the ultimate realizability of its net deferred tax assets, the Company considers all available evidence, including cumulative losses since inception and expected future losses and as such, management does not believe it is more likely than not that the deferred tax assets will be realized. Accordingly, a full valuation allowance has been established in the U.S. and no deferred tax assets and related tax benefit have been recognized in the accompanying financial statements. The valuation allowance as of April 30, 2024 and 2023 was $252.7 million and $180.6 million, respectively. The increase of $72.1 million in the Company’s valuation allowance compared to the prior fiscal year was primarily due to an increase in deferred tax assets arising from net operating loss and capitalized R&D expenses.
As of April 30, 2024 and 2023, the Company had net operating loss carryforwards for federal income tax purposes of approximately $599.3 million and $487.6 million, respectively. The federal net operating loss carryforwards will expire, if not utilized, beginning in year 2029. Federal research and development tax credit carryforwards of approximately $18.8 million, will expire beginning in 2032 if not utilized. Federal charitable contribution carryforwards of approximately $25.6 million will expire beginning in 2022 if not utilized. Federal capital loss carryforwards of approximately $1.0 million will begin to expire in 2026 if not utilized.
In addition, as of April 30, 2024 and 2023, the Company had net operating loss carryforwards for state income tax purposes of approximately $249.3 million and $187.8 million, respectively. The state net operating loss carryforwards will expire, if not utilized, beginning in the year 2032. The Company had state research and development tax credit carryforwards of approximately $14.2 million. The state research and development tax credits do not expire. State capitol loss carryforwards of approximately $0.4 million will begin to expire in 2026 if not utilized.
The Tax Reform Act of 1986 and similar California legislation impose substantial restrictions on the utilization of net operating losses and tax credit carryforwards if there is a change in ownership as provided by Section 382 of the Internal Revenue Code and similar state provisions. Such a limitation could result in the expiration of the net operating loss carryforwards and tax credits before utilization.
A reconciliation of the beginning and ending amount of the Company’s total gross unrecognized tax benefits was as follows (in thousands):
As of April 30,
20242023
Balance as of May 1$11,369 $7,368 
Increases for tax positions related to the current year5,179 4,001 
Balance as of April 30$16,548 $11,369 
As of April 30, 2024, $0.1 million of unrecognized tax benefits, if recognized, would impact the Company’s effective income tax rate. The Company does not expect any unrecognized tax benefits to be recognized within the next 12 months.
The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of April 30, 2024 and 2023, the Company has no cumulative interest and penalties related to unrecognized tax benefits. The Company does not anticipate a significant change in the unrecognized tax benefits over the next 12 months.